Effectiveness of antiviral treatment in preventing death in severe hospitalised influenza cases over six seasons

Epidemiology and Infection

Volumn 146, Issue 7, 2018, Pages 799-808

  Dominguez A ^a,b   Romero Tamarit, A ^b   Soldevila, N ^a,b   Godoy, P ^b,c   Jane M ^b,c   Martinez A ^b,c   Torner, N ^a,b,c   Cayla J A ^b,d   Rius, C ^b,d  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c GENERALITAT DE CATALUNYA   (Spain)

^d AGÈNCIA DE SALUT PÚBLICA DE BARCELONA   (Spain)

Author keywords

Adherence; adults; antiviral treatment; effectiveness; influenza

Indexed keywords

SIALIDASE INHIBITOR; ANTIVIRUS AGENT;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CATALONIA; DEATH; DISEASE SEVERITY; FEMALE; HOSPITALIZATION; HUMAN; INFLUENZA; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; OBSERVATIONAL STUDY; TIME TO TREATMENT; INFLUENZA A VIRUS (H1N1); MIDDLE AGED; PHYSIOLOGY; SEASON; SPAIN; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; FEMALE; HOSPITALIZATION; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; SEASONS; SPAIN; YOUNG ADULT;

EID: 85044631428     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268818000663     Document Type: Article

References (32)

1. World Health Organization. Questions and answers on immunization and vaccine safety. Available at http://www.who.int/features/qa/84/en/.
2. World Health Organization. Fact sheet on influenza. Available at http://www.who.int/mediacentre/factsheets/fs211/en/.
3. Treanor JJ (2015) Influenza (including avian influenza and swine influenza. In Bennet JE, Dolin R and Blaser MJ (eds). Principles and Practice of Infectious Diseases, 8th edn., Philadelphia, PA: Elsevier, pp. 2000-2024.
4. Harper SA, et al. (2009) Seasonal influenza in adults and childrendiagnosis, treatment, chemoprophylaxis., institutional outbreak management: Clinical practice guidelines of the Infectious Disease Society of America. Clinical Infectious Disease 48, 1003-1032.
5. Spagnuolo PJ, et al. (2016) Effects of antiviral treatment on influenzarelated complications over four influenza season: 2006-2010. Current Medical Research and Opinion 32, 1399-1407.
6. Lindegren ML, et al. (2015) Antiviral treatment among older adults hospitalized with influenza, 2006-2012. PLoS ONE 10, e0121952.
7. Agència de Salut Pública de Catalunya. Pla d'actuació a Catalunya enfront d'una infecció per virus de la grip en fase post-pandèmica. Available at http://canalsalut.gencat.cat/web/.content/home-canal-salut/professionals/temes-de-salut/grip/documents/grippostpan2010.pdf (Accessed 28 November 2017).
8. McGeer A, et al. (2007) Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clinical Infectious Disease 45, 1568-1575.
9. Martin ET (2017) Use of neuraminidase inhibitors for treatment of severe influenza: Times are changing. Clinical Infectious Disease 64, 368-369.
10. Michiels B, et al. (2013) The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: A systematic review of systematic reviews. PLoS ONE 8, e60348.
11. Hsu J, et al. (2012) Antivirals for treatment of influenza: A systematic review and meta-Analysis of observational studies. Annals of Internal Medicine 156, 512-524.
12. Lindegren ML and Schaffner W (2014) Treatment with neuraminidase inhibitors for high-risk patients with influenza: Why is adherence to antiviral treatment recommendations so low The Journal of Infection Disease 210, 510-513.
13. Agència de Salut Pública de Catalunya. Estratègia de Vigilància dels casos greus produïts per la infecció pel virus de la grip. Available at http://canalsalut.gencat.cat/web/.content/contingut-responsiu/salutAZ/G/Grip/documents/arxius/estrategia.pdf (Accessed 28 November 2017).
14. Centro Nacional de Epidemiologiá.Vigilancia de casos graves hospitalizados confirmados de virus de la gripe. Available at http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-Alertas/fd-enfermedades/Vigilancia-de-casos-graves-confirmados-de-virus-de-la-gripe-v. 08octubre2014.pdf (Accessed 28 November 2017).
15. Suwannakarn K, et al. (2008) Typing (A/B) and subtyping (H1/H3/H5) of influenza A viruses by multiplex real-time RT-PCR assays. Journal of Virological Methods 152, 25-31.
16. Katz MH (2011) Multivariable Analysis, 3rd edn., Cambridge, CBG: Cambridge University Press, pp. 88-92.
17. Appiah GD, et al. (2017) Increased antiviral treatment among hospitalized children and adults with laboratory-confirmed influenza, 2010-2015. Clinical Infectious Disease 64, 364-367.
18. Fernández S, et al. (2012) Analysis of confirmed severe cases of influenza in the first season after pandemic. Medicina Clinica 139, 84-87.
19. Maruyama T, et al. (2016) Outcomes and prognostic features of patients with influenza requiring hospitalization and receiving early antiviral therapy: A prospective multicentre cohort study. Chest 149, 526-534.
20. Shah NS, et al. (2015) Severe influenza in 33 US hospitals, 2013-2014: Complication and risk factors for death in 507 patients. Infection Control and Hospital Epidemiology 36, 1251-1260.
21. Xu C, et al. (2013) Characteristics of hospitalized cases with influenza A (H1N1)pdm09 infection during first winter season of post-pandemic in China. PLoS ONE 8, e55016.
22. Rolfes MA, et al. (2016) Respiratory viral testing and influenza antiviral prescriptions during hospitalization for acute respiratory illness. Open Forum Infectious Disease 3, ofv216.
23. Gutiérrez-Pizarraya A, et al. (2012) Unexpected severity of cases of influenza B infection in patients that required hospitalization during first postpandemic wave. The Journal of Infection 65, 423-430.
24. Hiba V, et al. (2011) Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): Retrospective cohort study. The Journal of Antimicrobial Chemotherapy 66, 1150-1155.
25. Lee N, et al. (2010) Outcomes of adults hospitalised with severe influenza. Thorax 65, 510-515.
26. Delgado-Rodríguez M, et al. (2012) Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: Influence of neuraminidase inhibitors. The Journal of Antimicrobial Chemotherapy 67, 1739-1745.
27. Muthuri SG, et al. (2014) Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza H1N1pdm09 virus infection: A meta-Analysis of individual participant data. The Lancet. Respiratory Medicine 2, 395-404.
28. Rodríguez A, et al. (2011) Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. The Journal of Antimicrobial Chemotherapy 66, 1140-1149.
29. Lee N, et al. (2013) Influenza virus load in hospitalized patients. Hong Kong Medical Journal 19, 15-18.
30. Louie JK, et al. (2012) Treatment with neuraminidase inhibitors for critically ill patients with influenza A(H1N1)pdm09. Clinical Infectious Disease 55, 1198-1204.
31. Yu H, et al. (2010) Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: Opportunistic retrospective study of medical charts in China. British Medical Journal 341, c4779.
32. Ayscue P, et al. (2014) Influenza-Associated intensive-care unit admissions and deaths-California, September 29, 2013-January 18, 2014. MMWR Morbidity and Mortality Weekly Report 63, 143-147.